Luca Vittorio Carlo Valenti

Transcription

1 PERSONAL INFORMATION Luca Vittorio Carlo Valenti , Corso Lodi 65C, Milan, 20139, Italy Researcher unique identifier(s): ORCID: , Researcher ID: B , SCOPUS Author ID: ; Sex M Date of birth 12/06/1975 Nationality Italian 2016-now 2018-now Associate professor of Internal Medicine, Università degli Studi di Physician scientist, Translational Medicine Department of Transfusione Medicine and Hematology, Fondazione IRCCS Ca Granda Ospedale Policlinico Milano, Italy WORK EXPERIENCE EDUCATION AND TRAINING PERSONAL SKILLS Mother tongue(s) Italian Other language(s) UNDERSTANDING SPEAKING WRITING Listening Reading Spoken interaction Spoken production English Enter level Enter level Enter level Enter level Enter level Replace with name of language certificate. Enter level if known. SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS 2008 Supervision of several graduate students, PhD students, Master Students, Postdocs, International fellows, Università degli Studi di Milano, Fondazione IRCCS Ca Granda Ospedale Policlinico, Milan, Italy TEACHING ACTIVITIES 2009 Lecturer, Internal Medicine, Medicine degree, Università degli Studi di Milano, Italy 2009 Lecturer, Emergency Medicine, Medicine degree, Università degli Studi di Milano, Italy European Union, europass.cedefop.europa.eu Page 1 / 5

2 Curriculum Vitae Replace with First name(s) Surname(s) 2009 Lecturer, Human Pathophysiology, Medical Biotechnologies degree, Università degli Studi di Milano, Italy 2009 Elective courses: Genetics in hepatology, and Metabolic liver diseases, residency in Internal Medicine Faculty of Medicine, Università degli Studi di Milano, Italy CLINICAL DUTIES Internal Medicine and Hepatology unit, Department of Transfusione Medicine and Hematology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan INSTITUTIONAL RESPONSIBILITIES 2008 Faculty member, Medicine and Surgery, Università degli Studi di Milano, Italy Scientific Committee, Fondazione IRCCS Ca Granda Policlinico, Milan, Italy Organizer of Ca Granda Seminars in Molecular Medicine, and of internal seminars Lunch sessions, Fondazione IRCCS Ca Granda, Milan, Italy 2012 Scientific Committee, Dept. of Pathophysiology and Transplantation, Università degli Studi di Board member of the Ph.D. School Clinical and Experimental Medicine, Università degli Studi di Member of the Committee for the supervision of experimental animal research, Fondazione IRCCS Ca Granda, Milan, Italy COMMISSIONS OF TRUST 2008 Reviewer for several international Journals (>60) including New England Journal of Medicine, The Lancet, Gastroenterology, Gut, Journal of Clinical Investigation, Hepatology, Journal of Hepatology, Nature Communications, Circulation, Diabetes, Blood, several Scientific Societies (EASL, AISF), European Institutions 2012 Review panel member, Italian Ministry of University and Research (MIUR), AIFA, Italian and other national governmental research agencies (e.g. France, Portugal, Israel, South Africa) 2012 Contributing associate editor-in-chief, World Journal of Gastroenterology 2013 Associate editor, BMC Gastroenterology Associate editor, Liver International Editorial Board, Clinical Science Editorial Board, Hepatology Communications, Journal of Hepatology Reports, ReAd Files Scientific National Habilitation (ASN), Italy, Full Professor of Internal Medicine and Full Professor of Gastroenterology FELLOWSHIPS AND AWARDS 2004 Emanuela Ruggerini Prize Università degli Studi di Milano for Metabolic Research 2006 Italian Society of Internal Medicine (SIMI) Research Prize 2012 Italian Association for the Study of Liver Diseases (AISF) Prize for the Best Italian Paper in Hepatology 2010 Several presentation awards at national scientific meetings: AISF 2001, 2007, 2010; SIMI 2006, 2007, 2008 MEMBERSHIPS OF SCIENTIFIC SOCIETIES 1999 Associated Member, Italian Association for the Study of the Liver (AISF), Italy; Member of the AISF Governing Board Member of the Board of the Fondazione Italiana Ricerca in Epatologia (FIRE) Coordinator of the AISF Rare Diseases Committee since Associated Member, International BioIron Society (IBIS) 2000 Associated Member, Italian Society of Internal Medicine (SIMI); Italy 2008 Associated Member, European Association for the Study of the Liver (EASL) Member of the board of the Italian Foundation for the Research in Hepatology (FIRE) SCIENTIFIC ACTIVITY My main research interest is understanding the molecular basis of metabolic liver diseases, including non-alcoholic fatty liver disease (NAFLD), iron overload disorders and hepatocellular carcinoma, and to apply these discoveries to the clinical management of patients. I use a variety of tools to understand liver disease ranging from epidemiological studies in large European Union, europass.cedefop.europa.eu Page 2 / 5

3 cohort of individuals with liver biopsies to human and molecular genetics to understand how a gene mutation results into a phenotype. I am a leading scientist in the molecular genetics of chronic liver disease. I was the first to identify the link between a mutation in the PNPLA3 gene and genetically determined liver fat accumulation with liver fibrosis and hepatocellular carcinoma. I also understood the mechanism underlying the association by performing cellular studies on a specific liver cell type namely hepatic stellate cells. In collaboration with my international network I have recently discovered new genetic determinants of non-alcoholic fatty liver disease. In the iron field, I have contributed to establishing the role of body iron accumulation in the pathogenesis of metabolic and cardiovascular complications of insulin resistance, and the therapeutic utility of iron deficiency. As epidemiologist, I am contributed defining the clinical risk factors, natural history, and therapies for NAFLD. From a clinical research prospect, I design and coordinate clinical translational research and spontaneous clinical trials of the Metabolic Liver Diseases Research Center at the Fondazione Ca Granda IRCCS, and I am conducting several sponsored trials in the field of non-alcoholic steatohepatitis (NASH). Author of 211 peer-reviewed papers; total impact factor = 1,379; average IF = papers as main author (67 as first, 57 as last, 84 as corresponding author; IF=863). Scholar: H-index 51, i10-index: 140; citation index 9,830; Scopus H-index: 44. I am considered an opinion leader in the field of metabolic liver diseases, as testified by invited talks and moderations of scientific sessions in scientific meetings and seminars in Italy, Europe, Asia, and the USA. Main collaborators: National: Paola Dongiovanni, Stefano Gatti, Marco Maggioni, (Fondazione IRCCS Ca Granda Milano), Alessio Aghemo, Massimo Colombo (Humanitas University, Milan), Raffaele De Francesco (INGM, Milano), Valerio Nobili (Ospedale Bambin Gesù, Roma), Massimiliano Ruscica e Patrizia Riso (Università degli Studi di Milano), Salvatore Petta (Università di Palermo), Elisabetta Bugianesi (Università di Torino), Alberto Piperno (Università Milano Bicocca) and Domico Girelli (Univesità di Verona). International: Stefano Romeo (University of Gotenburg, SE), Quentin Anstee, Helen Reeves, Chris Day (University of Newcastle, UK), Jussi Pihlajamaki (University of Kuopio, FI), Utpal Pajvani, Ira Tabas and Domenico Accili (Columbia University, NY, USA), Felix Stickel (University of Zurich, CH), Julia Kozlitina and Chao Xing (UT Southwestern, Dallas, TX). Main Grants: Hospital grants: internal competitive grants from the Università degli Studi di Milano and Fondazione IRCCS Ca Granda Milano, plus internal funding from the Fondazione IRCCS based on previous year impact factor. Bando Medicina Molecolare INGM - Policlinico 2014: EpIDEMIC HCC: Exome sequencing for the IDEntification of inherited Mutations Involved in hepatocellular Carcinoma (200,00.00) Bando Bando Direzione Scientifica utilizzo Piattaforme Interne (100,000.00) Study for the Evaluation of Risk of hepatocellular carcinoma in NonAlcoholic fatty liver (SERENA): A multicenter prospective cohort study for the evaluation of the interaction between congenital and acquired risk factors in the pathogenesis of hepatocellular carcinoma in patients with nonalcoholic fatty liver and disease risk stratification National grants: 1) Bando Giovani 2007 Ministero della Salute e delle Politiche Sociali (national coordinator; GR ): Euro 600,000.00; young investigator grant awarded by the Italian Ministry of Health 2) Bando Futuro in Ricerca MIUR 2009 (national coordinator): selected 3) Ministero della Salute e delle Politiche Sociali PRIN 2011/3 (participating researcher) 4) EPIDEMIC-HCC NAFLD: My First Grant AIRC N (Italian Association for Cancer Research) 5) Ricerca Finalizzata 2016, Change promoting: Impact of whole exome sequencing on the clinical management of patients with advanced nonalcoholic fatty liver and cryptogenic liver disease (national coordinator) RF , Euro 450,000.00, Italian Ministry of Health 6) Gilead Fellowship Program 2018 Evaluation of the risk of nonalcoholic steatohepatitis and association with progressive liver damage in a real-life cohort of patients who cleared hcv infection (navigator) Mentor of Young Investigators Grants: 1) Raffaela Rametta, AISF Fellowship 2015 and FIRE Fellowship ) Marica Meroni, FIRE Fellowship ) Vittorio Borroni, SIMI Research Prize 2017 International grants: 1) Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS), Investigative Medicines Initiative 2: Call 7 ( ) Identification and Validation of Non-invasive Markers across the Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD): Partner. H2020 IMI European Union, europass.cedefop.europa.eu Page 3 / 5

4 Curriculum Vitae Replace with First name(s) Surname(s) 2) MAST4Health: A multicenter randomized double-blind placebo-controlled (parallel arm) clinical trial on the efficacy of Mastiha supplement in NAFLD/NASH patients. Partner MSCA-RISE-2015/ H2020 MSCA-RISE-2015 MSCA GA number Top selected publications: Dongiovanni, P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine; 2018 First formal demonstration of a causal role of hepatic fat accumulation in determining progressive liver disease and insulin resistance by a Mendelian randomization approach. CI=8 Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, Borén J, Montalcini T, Pujia A, Wiklund O, Hindy G, Spagnuolo R, Motta BM, Pipitone RM, Craxì A, Fargion S, Nobili V, Käkelä P, Kärj V, Männistö V, Pihlajamäki J, Kozlitina J, Valenti L*, Romeo S. *Corresponding author. MBOAT7/TMC4 rs variant increases the risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150: doi: /j.gastro Identification of a new genetic risk variant for NASH and the implicated mechanism. CI=101 Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta1 R Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61: doi: /hep Epidemiological study detecting a protective impact of statin use on liver damage related to nonalcoholic steatohepatitis. CI=138 Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and nonalcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015;63: doi: /j.jhep First demonstration of the impact of a TM6SF2 variant on steatohepatitis, and of dissociation between hepatic and cardiovascular risk profile. CI=191 Valenti L, Rumi MG, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain containing-3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53: doi: /hep First demonstration of both a predisposing effect of the PNPLA3 variant on liver disease progression in chronic HCV infection, and of an independent effect on the risk of hepatocellular carcinoma. CI=222 Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the Patatin-like phospholipase domain containing-3 / adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51: doi: /hep First demonstration of the association of the PNPLA3 I148M variant with liver fibrosis in nonalcoholic fatty liver. CI=404 Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138: doi: /j.gastro Evaluation of the impact of hepatic iron on disease progression in patients with fatty liver. CI=197 Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia; evidence from a case control study. American Journal of Gastroenterology. 2007;102:1-8. doi: /j x Demonstration of the positive impact of iron depletion therapy on liver damage and metabolic alterations in patients with dysmetabolic hyperferritinemia. CI=250 Frescas D, Valenti L*, Accili D. *co-first author. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirtdependent deacetylation promotes expression of glucogenetic genes. Journal of Biological Chemistry. 2005;280: doi: /jbc.M Characterization of a molecular mechanism linking oxidative stress with hepatic insulin resistance. CI=483 Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology. 2002;122: doi: /gast Identification of a genetic link between predisposition to inflammation, insulin resistance and NASH. CI=355 Personal information I authorize the handling of personal information in this curriculum, according to D.Lgs n. 196/03 and following modifications and Regulations EU 679/2016 (General Regulations concerning Data Protection or GRDP) and art. 7 European Union, europass.cedefop.europa.eu Page 4 / 5

5 of University Regulations concerning protection of personal information. I authorize, according to D.lgs 14/03/2013 n. 33 concerning transparency, in case of conferment of the position and of the fellowship, the publication of this curriculum in the web site of Università degli Studi di Milano in the section Amministrazione trasparente, Consulenti e collaboratori. Date Signature 13/12/2018 European Union, europass.cedefop.europa.eu Page 5 / 5